Sensei Biotherapeutics, Inc.
SNSE
$0.3857
-$0.0192-4.74%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -34.61% | -32.99% | -32.18% | -18.00% | -4.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.91% | -22.13% | -32.34% | -28.17% | -25.75% |
| Operating Income | 16.91% | 22.13% | 32.34% | 28.17% | 25.75% |
| Income Before Tax | 11.57% | 23.43% | 34.37% | 31.16% | 29.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.57% | 23.43% | 34.37% | 31.16% | 29.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.57% | 23.43% | 34.37% | 31.16% | 29.82% |
| EBIT | 16.91% | 22.13% | 32.34% | 28.17% | 25.75% |
| EBITDA | 17.46% | 22.75% | 33.16% | 28.89% | 26.47% |
| EPS Basic | 1.05% | 9.56% | 19.86% | 20.21% | 23.32% |
| Normalized Basic EPS | 6.13% | 7.80% | 18.35% | 19.48% | 21.70% |
| EPS Diluted | 1.05% | 9.56% | 19.86% | 20.21% | 23.32% |
| Normalized Diluted EPS | 6.13% | 7.80% | 18.35% | 19.48% | 21.70% |
| Average Basic Shares Outstanding | -10.19% | -14.75% | -18.06% | -13.80% | -8.91% |
| Average Diluted Shares Outstanding | -10.19% | -14.75% | -18.06% | -13.80% | -8.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |